NCT05533359 is a NA clinical trial of Text-Messaging (TM) in COVID-19, sponsored by University of Utah.

Who is sponsoring NCT05533359?

NCT05533359 is sponsored by University of Utah.

What drugs are being tested in NCT05533359?

Interventions in NCT05533359: Text-Messaging (TM), Conversational Agent (CA), Patient Navigation (PN).

Is NCT05533359 still recruiting?

NCT05533359 is currently completed. Last updated 15 January 2025.

Are results published for NCT05533359?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-01-15 · How we verify

NCT05533359

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SCALE-UP Utah II: Community-Academic Partnership to Address COVID-19 Conversational Agent Study

Completed NA Results posted Last updated 15 January 2025

What this trial tests

NA trial testing Text-Messaging (TM) in COVID-19 in 2,117 participants. Completed in 30 November 2023.

Timeline

15 January 2023

Primary endpoint
30 November 2023

30 November 2023

Quick facts

Lead sponsor	University of Utah
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	screening
Enrollment	2,117
Start date	15 January 2023
Primary completion	30 November 2023
Estimated completion	30 November 2023
Sites	1 location across United States

Drugs / interventions tested

Text-Messaging (TM)
Conversational Agent (CA)
Patient Navigation (PN)

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

University of Utah

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Reach-Accept Testing Primary · Every 10 or 30 days dependent on group randomization [up to 90 days post intervention message] Every 10 or 30 days from intervention messaging for 90 days dependent on group randomization.

Number of patients who requested a test kit and confirmed their mailing address.

Group	Value	95% CI
Conversational Agent (CA) + No Patient Navigation (NoPN) + 10 Day	47
Conversational Agent (CA) + No Patient Navigation (PN) + 30 Day	41
Conversational Agent (CA) + Patient Navigation (PN) + 10 Day	41
Conversational Agent (CA) + Patient Navigation (PN) + 30 Day	45
Text Message (TM) + No Patient Navigation (NoPN) + 10 Day	142
Text Message (TM) + No Patient Navigation (NoPN) + 30 Day	139
Text Message (TM) + Patient Navigation (PN) + 10 Day	151
Text Message (TM) + Patient Navigation (PN) + 30 Day	123

Reach-Engage Testing Secondary · Every 10 or 30 days dependent on group randomization [up to 90 days post intervention message]

Number of patients that reply to an offer to receive an at-home rapid test kit

Group	Value	95% CI
Conversational Agent (CA) + No Patient Navigation (NoPN) + 10 Day	90
Conversational Agent (CA) + No Patient Navigation (PN) + 30 Day	73
Conversational Agent (CA) + Patient Navigation (PN) + 10 Day	78
Conversational Agent (CA) + Patient Navigation (PN) + 30 Day	68
Text Message (TM) + No Patient Navigation (NoPN) + 10 Day	155
Text Message (TM) + No Patient Navigation (NoPN) + 30 Day	154
Text Message (TM) + Patient Navigation (PN) + 10 Day	171
Text Message (TM) + Patient Navigation (PN) + 30 Day	145

PN-Request Secondary · Every 10 or 30 days dependent on group randomization [up to 90 days post intervention message]

Number of participants who were assigned to PN groups who requested patient navigation.

Group	Value	95% CI
Conversational Agent (CA) + No Patient Navigation (NoPN) + 10 Day	0
Conversational Agent (CA) + No Patient Navigation (PN) + 30 Day	0
Conversational Agent (CA) + Patient Navigation (PN) + 10 Day	3
Conversational Agent (CA) + Patient Navigation (PN) + 30 Day	3
Text Message (TM) + No Patient Navigation (NoPN) + 10 Day	0
Text Message (TM) + No Patient Navigation (NoPN) + 30 Day	0
Text Message (TM) + Patient Navigation (PN) + 10 Day	3
Text Message (TM) + Patient Navigation (PN) + 30 Day	1

PN-Engage Secondary · Every 10 or 30 days dependent on group randomization [up to 90 days post intervention message]

Number of participants who were in PN groups who talked to a patient navigator.

Group	Value	95% CI
Conversational Agent (CA) + No Patient Navigation (NoPN) + 10 Day	0
Conversational Agent (CA) + No Patient Navigation (PN) + 30 Day	0
Conversational Agent (CA) + Patient Navigation (PN) + 10 Day	2
Conversational Agent (CA) + Patient Navigation (PN) + 30 Day	2
Text Message (TM) + No Patient Navigation (NoPN) + 10 Day	0
Text Message (TM) + No Patient Navigation (NoPN) + 30 Day	0
Text Message (TM) + Patient Navigation (PN) + 10 Day	2
Text Message (TM) + Patient Navigation (PN) + 30 Day	0

Opt Out Secondary · Daily [up to 90 days post intervention message]

Number of participants who replied to stop receiving study interventions. Participants could opt-out at any time regardless of message timing.

Group	Value	95% CI
Conversational Agent (CA) + No Patient Navigation (NoPN) + 10 Day	14
Conversational Agent (CA) + No Patient Navigation (PN) + 30 Day	2
Conversational Agent (CA) + Patient Navigation (PN) + 10 Day	27
Conversational Agent (CA) + Patient Navigation (PN) + 30 Day	13
Text Message (TM) + No Patient Navigation (NoPN) + 10 Day	23
Text Message (TM) + No Patient Navigation (NoPN) + 30 Day	3
Text Message (TM) + Patient Navigation (PN) + 10 Day	15
Text Message (TM) + Patient Navigation (PN) + 30 Day	9

Self-reported Testing Secondary · 90 days post intervention message

Participant self-reported testing as completed. Reported only for participants who requested COVID-19 test kits from the study and responded to follow-up messages.

Group	Value	95% CI
Conversational Agent (CA) + No Patient Navigation (NoPN) + 10 Day	18
Conversational Agent (CA) + No Patient Navigation (PN) + 30 Day	16
Conversational Agent (CA) + Patient Navigation (PN) + 10 Day	13
Conversational Agent (CA) + Patient Navigation (PN) + 30 Day	13
Text Message (TM) + No Patient Navigation (NoPN) + 10 Day	32
Text Message (TM) + No Patient Navigation (NoPN) + 30 Day	37
Text Message (TM) + Patient Navigation (PN) + 10 Day	41
Text Message (TM) + Patient Navigation (PN) + 30 Day	25

Sponsor's own description

The long-term objective of SCALE-UP II is to increase the reach, uptake, and sustainability of COVID-19 testing among underserved populations. Through RADx-UP Phase I funding (SCALE-UP Utah), the team has established population health management (PHM) interventions that have been used since Feb 2021 to increase the uptake of COVID-19 testing and vaccination among community health center patients. Interventions are based on a PHM approach that uses widely available technology (i.e. cell phones and text messaging). SCALE-UP II will both build on SCALE-UP Utah PHM interventions and investigate novel resource conservation approaches (i.e., Request-Patient Navigation vs. No Patient Navigation and text messaging vs. conversational agent). SCALE-UP II builds on long standing partnerships among the University of Utah Clinical and Translational Science Institute (UofU CTSI), Association for Utah Community Health (AUCH), CHCs, and the Utah Department of Health(UDOH). CTSI and SCALE-UP II investigators are leading several COVID-19 initiatives that drive public health response and state government policies in Utah. Thus, the UofU team is uniquely positioned to lead this project.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Population-Based Digital Health Interventions to Deliver at-Home COVID-19 Testing: SCALE-UP II Randomized Clinical Trial.
Del Fiol G, Kuzmenko TV, Orleans B, Chipman JJ, et al · · 2025 · cited 2× · PMID 40720824 · DOI 10.2196/74145
SCALE-UP II: protocol for a pragmatic randomised trial examining population health management interventions to increase the uptake of at-home COVID-19 testing in community health centres.
Del Fiol G, Orleans B, Kuzmenko TV, Chipman J, et al · · 2024 · cited 1× · PMID 38508633 · DOI 10.1136/bmjopen-2023-081455

Verify or expand the search:

Other trials of Text-Messaging (TM)

Trials testing the same drug.

NCT05533918 — SCALE-UP Utah II: Community-Academic Partnership to Address COVID-19 Text Message Study · NA · completed
NCT04939519 — SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Vaccination Rates Among Utah Community Health Centers · NA · completed
NCT04939532 — SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Testing Among Utah Community Health Centers · NA · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other University of Utah trials

Trials by the same sponsor.

NCT07515755 — Supplemental Oxygen and Oxygen Desaturations in Colonoscopies · NA · not yet recruiting
NCT07225426 — Personalizing Financial Incentives · NA · recruiting
NCT06716411 — Confirming the Effects of Acupuncture Treatments to Relieve Symptoms of Gulf War Illness · NA · recruiting
NCT07246538 — Positive Airway Pressure (PAP) System Evaluation in Volunteers · NA · not yet recruiting
NCT04208984 — Diversion Device With Breath Control · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05533359 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Utah
Last refreshed: 15 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05533359.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing